Financials

v3.19.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 5,909 $ 9,295
Restricted cash 0 361
Receivables 2,052 1,737
Inventory 1,246 1,262
Contract assets 0 99
Prepaid expenses and other current assets 882 547
Total current assets 10,089 13,301
Property and equipment, net 782 794
Operating lease right-of-use asset 569 0
Total assets 11,440 14,095
Current liabilities:    
Accounts payable 1,204 1,526
Accrued clinical trials expenses 666 620
Accrued sales allowances 887 0
Other accrued liabilities 534 466
Deferred revenue 0 313
Operating lease liability, current 243 0
Current portion of long-term debt 1,227 527
Total current liabilities 4,761 3,452
Operating lease liability, non-current 357 0
Long-term debt 3,242 3,787
Derivative liability 25 25
Total liabilities 8,385 7,264
Stockholders' equity:    
Common stock, at amounts paid-in 13 13
Additional paid-in capital 340,138 339,397
Accumulated deficit (337,096) (332,579)
Total stockholders' equity 3,055 6,831
Total liabilities and stockholders' equity $ 11,440 $ 14,095

Source

v3.19.1
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenues:    
License revenue $ 313 $ 1,064
Product revenue 317 0
Grant revenue 315 0
Total revenues 945 1,064
Operating expenses:    
Cost of goods sold 304 0
Research and development 1,844 1,856
Selling, general and administrative 3,082 1,615
Total operating expenses 5,230 3,471
Loss from operations (4,285) (2,407)
Other expense:    
Interest expense, net (246) (198)
Other income, net 14 0
Other expense, net (232) (198)
Net loss and comprehensive loss $ (4,517) $ (2,605)
Basic and diluted net loss per common share $ (0.34) $ (0.74)
Weighted average shares used in computing basic and diluted net loss per common share 13,217 3,534

Source

v3.19.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash flows from operating activities:    
Net loss $ (4,517) $ (2,605)
Adjustments to reconcile loss to net cash used in operating activities:    
Depreciation and amortization 60 112
Non-cash interest expense 169 85
Stock-based compensation 136 432
Other (14) 0
Changes in operating assets and liabilities:    
Receivables (315) 38
Inventory 16 0
Contract assets 99 (72)
Prepaid expenses and other assets (335) (243)
Accounts payable (326) (476)
Accrued sales allowances 887 0
Other accrued liabilities 145 321
Deferred revenue (313) 1,409
Net cash used in operating activities (4,308) (999)
Cash flows from investing activities:    
Purchases of property and equipment (44) (58)
Net cash used in investing activities (44) (58)
Cash flows from financing activities:    
Net proceeds from the exercises of common stock warrants 605 0
Payments of long-term debt 0 (3,000)
Net cash provided by (used in) financing activities 605 (3,000)
Net decrease in cash and cash equivalents (3,747) (4,057)
Cash, cash equivalents and restricted cash at beginning of period 9,656 7,883
Cash, cash equivalents and restricted cash at end of period 5,909 3,826
Supplemental disclosure of cash flow information:    
Interest paid 109 123
Warrants issued 0 470
Purchases of property and equipment included in accounts payable 3 0
Schedule of non-cash transactions    
Cash and cash equivalents 5,909 3,465
Restricted cash 0 361
Cash, cash equivalents and restricted cash shown in the statement of cash flows $ 5,909 $ 3,826

Source